Outdoor Report for Friday, May 22 ...

International leaders in industry, technology, education, and culture will explore actionable solutions to pressing worldwide challenges during the Brother Andrew Gonzalez FSC Academia-Industry ...

Phase 3 LIBRETTO-432 study evaluating Retevmo (selpercatinib) as adjuvant therapy in RET fusion-positive NSCLC to be featured in the Plenary Session and ASCO press program Investigator-initiated study ...

Jaypirca (pirtobrutinib) (pronounced jay-pihr-kaa) is a highly selective (300 times more selective for BTK versus 98% of other kinases tested in preclinical studies), non-covalent inhibitor of the ...